Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2021

View Archived Issues

MiR-30c mimics ameliorate liver fibrosis in vivo

Targeting tenascin-C could reduce the effects of retinal ischemia

FDA clears IND for investigational microbiome therapeutic SER-155

Immutep and Merck KGaA collaborate on phase I/II study of eftilagimod alpha plus bintrafusp alfa

Viracta initiates global pivotal study of nanatinostat plus valganciclovir in EBV+ lymphoma

Novel inhalable liposome formulations of antiviral drugs against COVID-19

Revolution Medicines discloses SOS1 inhibitors

Heptares Therapeutics patents GPR52 agonists

Dana-Farber Cancer Institute presents new PROTACs

Ventyx Biosciences synthesizes new TYK2 ligands

Valo Early Discovery identifies new HDAC8 inhibitors

NIH announces first-in-human study of FluMos-v1 universal influenza vaccine

Copeptin is a prognostic marker in schizophrenia spectrum disorder

Diverse cohort expands diabetes genomics

Transine Therapeutics secures funding to advance its novel class of therapeutic RNAs

Irisin and nucleobindin-2 predict cardiovascular risk in patients with NFAI

ATG3 gene is implicated in the development of NAFLD

N-803 shows safety and efficacy in combination with rituximab in iNHL

MCAD as novel therapeutic target for glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...